These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33839885)

  • 21. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement.
    Barbash IM; Ben-Dor I; Dvir D; Maluenda G; Xue Z; Torguson R; Satler LF; Pichard AD; Waksman R
    Am Heart J; 2012 Jun; 163(6):1031-6. PubMed ID: 22709757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.
    Verdoia M; Barbieri L; Parodi G; Bellandi B; Schaffer A; Suryapranata H; De Luca G
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):553-565. PubMed ID: 28471057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
    Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
    Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
    J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention.
    Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bivalirudin versus unfractionated heparin during peripheral vascular interventions: A Propensity-matched Study.
    Ortiz D; Singh M; Jahangir A; Allaqaband S; Khitha J; Bajwa TK; Mewissen MW
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):408-413. PubMed ID: 27526661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and effect of acute kidney injury after transcatheter aortic valve replacement using the new valve academic research consortium criteria.
    Généreux P; Kodali SK; Green P; Paradis JM; Daneault B; Rene G; Hueter I; Georges I; Kirtane A; Hahn RT; Smith C; Leon MB; Williams MR
    Am J Cardiol; 2013 Jan; 111(1):100-5. PubMed ID: 23040657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10years.
    Chaudry HI; Curran TB; Andrus BW; Conley SM; DeVries JT
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):338-342. PubMed ID: 29055661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
    Kiser TH; MacLaren R; Fish DN; Hassell KL; Teitelbaum I
    Pharmacotherapy; 2010 Nov; 30(11):1117-26. PubMed ID: 20973685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transapical versus transfemoral approach and risk of acute kidney injury following transcatheter aortic valve replacement: a propensity-adjusted analysis.
    Thongprayoon C; Cheungpasitporn W; Srivali N; Harrison AM; Kittanamongkolchai W; Greason KL; Kashani KB
    Ren Fail; 2017 Nov; 39(1):13-18. PubMed ID: 27767371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry.
    Chieffo A; Petronio AS; Mehilli J; Chandrasekhar J; Sartori S; Lefèvre T; Presbitero P; Capranzano P; Tchetche D; Iadanza A; Sardella G; Van Mieghem NM; Meliga E; Dumonteil N; Fraccaro C; Trabattoni D; Mikhail G; Sharma S; Ferrer MC; Naber C; Kievit P; Baber U; Snyder C; Sharma M; Morice MC; Mehran R;
    JACC Cardiovasc Interv; 2018 Jan; 11(1):1-12. PubMed ID: 29301640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis.
    Olmedo W; Villablanca PA; Sanina C; Walker J; Weinreich M; Brevik J; Avendano R; Bravo CA; Romero J; Ramakrishna H; Babaev A; Attubato M; Hernandez-Suarez DF; Cox-Alomar P; Pyo R; Krishnan P; Wiley J
    Vascular; 2019 Feb; 27(1):78-89. PubMed ID: 30501582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
    Liang Z; Li Y; Wang J; Wang D; Wang S; Ma L; Liu H; Yang L; Stone GW; Han Y
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():608-15. PubMed ID: 26762481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
    Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial.
    Goel R; Power D; Tchetche D; Chandiramani R; Guedeney P; Claessen BE; Sartori S; Cao D; Meneveau N; Tron C; Dumonteil N; Widder JD; Hengstenberg C; Ferrari M; Violini R; Stella PR; Jeger R; Anthopoulos P; Deliargyris EN; Mehran R; Dangas GD
    Int J Cardiol; 2019 Dec; 297():22-29. PubMed ID: 31630816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation.
    Lange P; Greif M; Bongiovanni D; Thaumann A; Näbauer M; Bischoff B; Helbig S; Becker C; Schmitz C; D'Anastasi M; Mehilli J; Boekstegers P; Massberg S; Kupatt C
    Can J Cardiol; 2015 Aug; 31(8):998-1003. PubMed ID: 26211708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.